Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05401175 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hematopoietic Stem Cell-containing Autologous Blood Reinfusion for Bone Marrow Protection in Cervical Cancer Patients

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Apr 2025 to Apr 2027
    • Study completion date: Apr 2027 to Apr 2029
    • Study title shortened, about 1 word
    v4
  2. Study title expanded, about 4 wordsv3
  3. Secondary endpoints revised (4)
    • Eligibility criteria expanded, about 2 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this project is to promote the reconstruction of haematopoietic function after chemoradiotherapy for cervical cancer with the innovative use of autologous haematopoietic containing stem cell blood transfusion support.To explore the effect of stored hemopoietic stem cell support therapy on bone marrow protection after concurrent chemoradiotherapy, in order to promote its clinical application.
Trial Details
NCT Number NCT05401175
Lead Sponsor Chongqing University Cancer Hospital
Conditions
(from sponsor)		 Cervical Cancer
Related terms Uterine Cervical Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov